19 ms·
In the earliest trial of Moderna’s mRNA-based vaccine, study participants received one of three dose levels: 25, 100 or 250 micrograms. The top dose proved too
by Animats 5y ago
In the earliest trial of Moderna’s mRNA-based vaccine, study participants received one of three dose levels: 25, 100 or 250 micrograms. The top dose proved too toxic. The low dose elicited the weakest immune response. The middle dose seemed to offer the best balance: it triggered strong immunity and had acceptable side effects.
That somewhat contradicts the article's claim.
If you under-dose, there may have to be a booster shot. Then the whole inoculation program has to do the job twice.
- saddlerustle 5y ago100% of the population with 70% immunity results in far fewer deaths than 25% of the population with 90% immunity
- belltaco 5y agoI think that calculation will vary depending on age and at risk groups. If those 25% in the second option are older folks and/or obese/diabetic, deaths might be lower in that scenario.
- voidfunc 5y ago100% of the population is unrealistic tho. In the US were looking at realistically somewhere around 65-70%… stronger immunity is desirable here
- Animats 5y agoWe can do better than 65-70%. Here in San Mateo County, CA, 86.6% of the population over 12 has been vaccinated. Local authorities are pushing to get that higher, because there are still some cases. "Our on-the-ground experience is that we have a steady flow of positive cases – 22 new cases since yesterday, people requiring hospitalization (7 today) and supports to quarantine and isolate (6 in hotel rooms) – and that the majority of these are members of our remaining unvaccinated population ages 12+." - San Mateo County health officer. 1 death in the county this week. Moderna is adding more production lines.
- handmodel 5y agoThe difference is that in that trial they weren't looking at health outcomes. They were looking at people's blood and measuring antibodies. If it turns out that 25mg produces a small amount of antibodies - but that small amount is still more than enough to prevent the same number of hospitalizations that 100mg does - then it make sense to go with that. The dosage trials were only used to study the microbiology. Not the death/hospitalization outcomes.
- makomk 5y agoThe risk is that even if that lower dose with a lower antibody response works fine with existing variants, it might not fare so well against future mutations. I think this has already happened to a certain extent with the currently circulating variants - vaccination programs that gave worse antibody responses fared OK against the original variant, but not so well against newer ones.
- handmodel 5y agoI think that is fair but I also find the status quo bias strange. If you think that variant changing is a bigger deal than getting them out fast what makes you so sure we shouldn't increase dosage another 50% or another booster? Right now it seems like the mRNA vaccines work fine and the variants are actually getting better at spreading but not killing.
- mikem170 5y ago> the variants are actually getting better at spreading but not killing I've heard that this is not unexpected, that it's to a viruses advantage to not kill people. That would jive with the fact that the several already endemic coronaviruses are much less likely that sars-cov-2 to cause severe problems.
- Zevis 5y agoWe don't need perfect immunity. Canada has shown that focusing on first doses over "full" immunity can work quite well at a population level. The flu vaccine is around 10-40% effective. Bu suddenly we pretend like if a vaccine doesn't give us 98% immunity, it's useless? Seriously?